Comorbidities Affect PCa Patient Death Risk
ORLANDO—Overall mortality among men with localized prostate cancer (PCa) increases with their burden of comorbid conditions, according to study findings presented at the fourth annual Genitourinary Cancers Symposium.
Among men aged 66-74 years who have stage T1c cancer and a Gleason score of 5-7 at diagnosis, the 10-year overall mortality rates were 28.8%, 50.5%, 83.1% for patients with Charlson score 0, 1, and 2 or more, respectively, the study found. PCa-specific mortality rates were 4.8%, 2.0%, and 5.3%, respectively.
Among men with T1c disease and a Gleason score of 8-10 at diagnosis, the 10-year overall mortality rates were 55.0%, 52.0%, 64.3%, respectively, and the PCa-specific mortality rates were 25.7%, 20.2%, and 13.7%, respectively.
Researchers led by Grace L. Lu-Yao, PhD, an epidemiologist at The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in New Brunswick, based their findings on a study of 19,639 men aged 66 years and older identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. The researchers classified patients according to their Charlson score, a measure of a patient's underlying conditions that is one of the strongest predictors of long-term survival. The higher the score, the greater a patient's comorbidity burden.
The study population included 14,130, 3,535, and 1,974 men with a Charlson score of 0, 1, and 2 or more, respectively.
Dr. Lu-Yao, who presented study findings, concluded that patients and clinicians should consider using comorbidity-specific data to estimate the threat posed by localized PCa.